Breaking News Instant updates and real-time market news.

NKTR

Nektar

$103.74

0.97 (0.94%)

04:56
04/13/18
04/13
04:56
04/13/18
04:56

Nektar assumed with an Overweight at Piper Jaffray

Piper Jaffray analyst Tyler Van Buren assumed coverage of Nektar Therapeutics with an Overweight rating and $125 price target. The analyst assumes approval of NKTR-181 for moderate to severe pain next year and the successful development of NKTR-214 in the first-line melanoma, first-line renal cell carcinoma, and second-line non-small cell lung cancer settings. He expects the American Society of Clinical Oncology meeting in June to be positive for Nektar shares.

  • 14

    Apr

  • 03

    May

  • 08

    May

  • 12

    Jun

NKTR Nektar
$103.74

0.97 (0.94%)

03/02/18
ADAM
03/02/18
NO CHANGE
Target $94
ADAM
Buy
Nektar price target raised to $94 from $80 at Canaccord
Canaccord Genuity analyst Arlinda Lee raised her price target for Nektar Therapeutics to $94 after the company reported Q4 results. Notable, Nektar provided a second update to Phase 1 Pivot-2 dose-escalation results indicating ongoing and further tumor shrinkage with improved and continuing response, Lee tells investors in a research note. Further, the company reported 60% response rate in 20 patients with PDL1-negative tumors at baseline, the analyst adds. She believes the update "further solidifies the central positioning" for wholly-owned drug candidate NKTR-214 in combination with anti-PD1. The analyst keeps a Buy rating on Nektar.
04/02/18
HCWC
04/02/18
INITIATION
Target $125
HCWC
Buy
Nektar assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay assumed coverage of Nektar Therapeutics with a Buy rating and $125 price target. The stock has had a "stellar run, but activity in checkpoint refractory patients could be well received," Chattopadhyay tells investors in a research note. The analyst believes available data from NKTR-214 in combination with Opdivo points to "compelling clinical activity." He sees "significant upside to the stock" beyond what his $125 target suggests should the data hold up to scrutiny.
04/06/18
MZHO
04/06/18
NO CHANGE
Target $103
MZHO
Buy
Mizuho says failure of Incyte's epacadostat ups chances of Nektar takeover
Mizuho analyst Difei Yang raised her price target on Nektar Therapeutics (NKTR) to $103 from $89 after Incyte (INCY) announced this morning the failure of epacadostat in combination with Merck's (MRK) Keytruda in a phase 3 study in melanoma patients. Recent clinical data presented by Nektar reinforced her view of NKTR-214 as one of the most impressive combo agent for checkpoint inhibitors, said Yang, who believes that the failure of epacadostat raises the possibility of a takeout by Bristol-Myers (BMY) in the coming months. She maintains a Buy rating on Nektar shares, which are down 8.5% to $92.75 in afternoon trading.
04/09/18
HCWC
04/09/18
NO CHANGE
Target $125
HCWC
Buy
Nektar data 'more robust' than Incyte's, says H.C. Wainwright
The failure of Incyte (INCY) and Merck's (MRK) Phase 3 study negatively impacted trading in Nektar Therapeutics (NKTR) shares on Friday, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note titled "Collateral Damage Not Surprising; Expecting ASCO-18 to Validate the Master T Cell Regulator Hypothesis." At this year's American Society of Clinical Oncology meeting, the analyst expects Nektar and partner Bristol-Myers Squibb (BMY) to unveil data from at least 40 advanced melanoma patients "supported by in-depth biomarker characterization to comprehensively ascertain the rationale of combining NKTR-214 with Opdivo." The rationale for combining NKTR-214 with Opdivo is "more robust" than epacadostat plus Keytruda, the analyst contends. Further, he believes data generated by the NKTR-214 plus Opdivo combination is "unambiguous." Chattopadhyay reiterates a Buy rating on Nektar shares with a $125 price target.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
07/16/18
07/16
10:17
07/16/18
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
07/16/18
07/16
10:16
07/16/18
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
07/16/18
07/16
10:15
07/16/18
10:15
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

10:15
07/16/18
07/16
10:15
07/16/18
10:15
General news
Treasury Action: yields remained elevated »

Treasury Action: yields…

NFLX

Netflix

$399.49

3.57 (0.90%)

, PH

Parker-Hannifin

$157.79

-3.79 (-2.35%)

10:14
07/16/18
07/16
10:14
07/16/18
10:14
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

NFLX

Netflix

$399.49

3.57 (0.90%)

PH

Parker-Hannifin

$157.79

-3.79 (-2.35%)

ROK

Rockwell Automation

$168.02

-3.1 (-1.81%)

FDX

FedEx

$231.55

-2.2 (-0.94%)

HAS

Hasbro

$94.14

-2.365 (-2.45%)

XON

Intrexon

$14.90

-0.48 (-3.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 23

    Jul

  • 25

    Jul

  • 17

    Sep

  • 20

    Sep

  • 21

    Sep

NFLX

Netflix

$399.49

3.57 (0.90%)

, PH

Parker-Hannifin

$157.79

-3.79 (-2.35%)

10:14
07/16/18
07/16
10:14
07/16/18
10:14
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

NFLX

Netflix

$399.49

3.57 (0.90%)

PH

Parker-Hannifin

$157.79

-3.79 (-2.35%)

ROK

Rockwell Automation

$168.02

-3.1 (-1.81%)

FDX

FedEx

$231.55

-2.2 (-0.94%)

HAS

Hasbro

$94.14

-2.365 (-2.45%)

XON

Intrexon

$14.90

-0.48 (-3.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 23

    Jul

  • 25

    Jul

  • 17

    Sep

  • 20

    Sep

  • 21

    Sep

WFC

Wells Fargo

$56.39

1.04 (1.88%)

, VFC

VF Corp.

$87.64

2.8 (3.30%)

10:14
07/16/18
07/16
10:14
07/16/18
10:14
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

WFC

Wells Fargo

$56.39

1.04 (1.88%)

VFC

VF Corp.

$87.64

2.8 (3.30%)

UPS

UPS

$111.28

2.3 (2.11%)

ALV

Autoliv

$106.19

0.46 (0.44%)

SAR

Saratoga Investment

$24.31

-0.32 (-1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 20

    Jul

  • 23

    Jul

  • 06

    Aug

  • 07

    Aug

  • 08

    Aug

  • 12

    Apr

  • 13

    Jul

  • 15

    Oct

BAC

Bank of America

$29.10

0.565 (1.98%)

10:14
07/16/18
07/16
10:14
07/16/18
10:14
Hot Stocks
Bank of America reports June default rate 2.66% vs. 2.98% last month »

Reports 30-plus day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

RDY

Dr. Reddy's

$30.40

-2.86 (-8.60%)

10:13
07/16/18
07/16
10:13
07/16/18
10:13
Technical Analysis
Technical Take: Dr. Reddy's falls after injunction against Suboxone generic »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOGO

Gogo

$3.86

-0.17 (-4.22%)

10:10
07/16/18
07/16
10:10
07/16/18
10:10
Recommendations
Gogo analyst commentary  »

Gogo transformation plan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOXA

21st Century Fox

$46.67

-0.885 (-1.86%)

10:10
07/16/18
07/16
10:10
07/16/18
10:10
Options
Repeat of bullish three-way spreads in 21st Century Fox »

Repeat of bullish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

10:10
07/16/18
07/16
10:10
07/16/18
10:10
General news
U.S. business inventories rose 04% in May, with sales up 1.4%, as forecast »

U.S. business inventories…

CNXN

Connection

$34.08

(0.00%)

10:03
07/16/18
07/16
10:03
07/16/18
10:03
Downgrade
Connection rating change  »

Connection downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$308.63

-10.17 (-3.19%)

10:01
07/16/18
07/16
10:01
07/16/18
10:01
Technical Analysis
Technical Take: Tesla has a small potential bearish pattern »

The shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:01
07/16/18
07/16
10:01
07/16/18
10:01
General news
Business Inventories data reported »

May Business Inventories…

SBH

Sally Beauty

$15.59

-0.78 (-4.76%)

10:00
07/16/18
07/16
10:00
07/16/18
10:00
Hot Stocks
Sally Beauty falls -4.9% »

Sally Beauty is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

ADS

Alliance Data

$229.04

-14.45 (-5.93%)

10:00
07/16/18
07/16
10:00
07/16/18
10:00
Hot Stocks
Alliance Data falls -5.9% »

Alliance Data is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

RDY

Dr. Reddy's

$30.50

-2.76 (-8.30%)

10:00
07/16/18
07/16
10:00
07/16/18
10:00
Hot Stocks
Dr. Reddy's falls -8.1% »

Dr. Reddy's is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWT

Britannia Bulk

$7.20

0.39 (5.73%)

10:00
07/16/18
07/16
10:00
07/16/18
10:00
Hot Stocks
Britannia Bulk rises 5.6% »

Britannia Bulk is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QEP

QEP Resources

$12.34

-0.42 (-3.29%)

10:00
07/16/18
07/16
10:00
07/16/18
10:00
Options
3K Qep Resources Aug 13 - 14 call spreads bought for 33c »

3K Qep Resources Aug 13 -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 19

    Aug

DB

Deutsche Bank

$12.11

0.865 (7.70%)

10:00
07/16/18
07/16
10:00
07/16/18
10:00
Hot Stocks
Deutsche Bank rises 7.7% »

Deutsche Bank is up 7.7%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARNC

Arconic

$19.17

1.78 (10.24%)

10:00
07/16/18
07/16
10:00
07/16/18
10:00
Hot Stocks
Arconic rises 10.3% »

Arconic is up 10.3%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMC

Honda

$29.29

-0.01 (-0.03%)

09:55
07/16/18
07/16
09:55
07/16/18
09:55
Downgrade
Honda rating change  »

Honda downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

VFC

VF Corp.

$87.06

2.22 (2.62%)

, PNC

PNC Financial

$139.80

2.46 (1.79%)

09:55
07/16/18
07/16
09:55
07/16/18
09:55
Options
Early notable gainers among liquid option names on July 16th »

Notable gainers among…

VFC

VF Corp.

$87.06

2.22 (2.62%)

PNC

PNC Financial

$139.80

2.46 (1.79%)

C

Citi

$68.39

1.39 (2.07%)

WFC

Wells Fargo

$56.41

1.06 (1.92%)

CFG

Citizens Financial

$40.02

0.66 (1.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 20

    Jul

  • 20

    Jul

  • 26

    Jul

  • 12

    Oct

  • 19

    Oct

  • 14

    Jan

  • 12

    Apr

  • 15

    Apr

  • 13

    Jul

  • 13

    Jul

  • 15

    Oct

  • 15

    Oct

IIIV

i3 Verticals

$16.73

(0.00%)

09:53
07/16/18
07/16
09:53
07/16/18
09:53
Initiation
i3 Verticals initiated  »

i3 Verticals initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.